MARLBOROUGH, Mass.,
May 18, 2020 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) completed a
public offering of $1.7 billion
aggregate principal amount of its senior notes. The public offering
consists of $500.0 million of 1.900%
notes due 2025 and $1.2 billion of
2.650% notes due 2030.
The company intends to use the net proceeds from this offering
towards (i) refinancing $450.0
million of borrowings under its revolving credit facility
and a portion of its pre-payable bank debt, including $750.0 million under its $1.0 billion term loan credit facility maturing
in February 2021 and $500.0 million under its $1.25 billion term loan credit facility maturing
in April 2021 and (ii) paying related
fees, expenses and premiums.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for 40 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E, of the Securities Exchange
Act of 1934, as amended. Forward-looking statements may be
identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend," "aiming" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding our proposed offering and intended use
of proceeds. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, political, competitive, reimbursement and
regulatory conditions; new product introductions; expected pricing
environment; demographic trends; intellectual property; litigation;
financial market conditions; and future business decisions made by
us and our competitors. New risks and uncertainties may arise
from time to time and are difficult to predict, including those
that have emerged or have increased in significance or likelihood
as a result of the COVID-19 pandemic. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of
these and other important risks and uncertainties that may affect
our future operations, see Part I, Item 1A - Risk
Factors in our most recent Annual Report on Form 10-K filed
with the Securities and Exchange Commission, which we may update in
Part II, Item 1A - Risk Factors in Quarterly Reports on
Form 10-Q we have filed or will file hereafter. We disclaim
any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this
press release.
|
|
|
|
|
|
CONTACT:
|
|
|
|
|
Media:
|
Kate
Haranis
|
|
Investors:
|
Susie Lisa,
CFA
|
|
508-683-6585
(office)
|
|
|
508-683-5565
(office)
|
|
Media
Relations
|
|
|
Investor
Relations
|
|
Boston Scientific
Corporation
|
|
|
Boston Scientific
Corporation
|
|
kate.haranis@bsci.com
|
|
|
BSXInvestorRelations@bsci.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-completes-1-7-billion-offering-of-senior-notes-301060859.html
SOURCE Boston Scientific Corporation